Does the UK Medicines Regulator Approve Most Cannabis Products?

The discussion around cannabis, cannabis-derived products, and their legal and medical status in the UK is often clouded by confusion and a mix of legal terms—especially around Class and Schedule classifications. With important changes made in November 2018, many wonder if the UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), approves most cannabis products, allowing widespread legal access. Spoiler: the picture is far more complex.

This post will clarify the key distinctions concerning cannabis regulation, explain what changed in late 2018, and outline why licensed cannabis medicines remain limited and specialist-only in the NHS. We'll also use real-world examples, including companies like Nationwide Pharmacies, to illustrate current prescribing and availability.

Understanding Class vs Schedule: Clearing Up Common Confusions

Before we dive into regulatory approvals, it’s important to clarify two often-misused terms:

• Class refers to the classification of drugs under the UK Misuse of Drugs Act 1971, which categorises drugs as Class A, B, or C based on their perceived harmfulness and sentencing guidelines. Cannabis is currently a Class B drug.
• Schedule refers to the classification under the Misuse of Drugs Regulations 2001, which regulates the legal possession and supply for medical, scientific, or industrial uses. Cannabis-based products for medicinal use are generally Schedule 2 or Schedule 4 substances.

This distinction matters because “legalisation” or “decriminalisation” claims often confuse Class status (legal under criminal law) with Schedule status (legal for medical use). Cannabis remains a Class B controlled drug, meaning recreational use and possession are illegal and can lead to prosecution. However, some cannabis-derived private medical cannabis uk medicines are now listed under appropriate Schedules, allowing licensed medical prescribing.

Takeaway: Class pertains to criminal law penalties; Schedule governs medical and scientific use – these do not mean the same thing.

What Changed in November 2018?

In November 2018, the UK government announced an important policy change: specialist doctors could legally prescribe cannabis-based products for medicinal use, a significant shift from the previous blanket ban on prescribing cannabis-derived medicines.

This change occurred following recognition of public pressure, clinical evidence, and high-profile cases where children with severe epilepsy or patients with multiple sclerosis found relief. Because of this:

• Cannabis-based products for medicinal use (CBPMs) were rescheduled, allowing specialist-only prescriptions to patients with exceptional clinical need.
• The MHRA continued to regulate cannabis medicines as any other medicines, assessing their safety, quality, and efficacy.
• Unlicensed cannabis-based products could be prescribed on a case-by-case basis ("unlicensed prescribing basis"), but this demands careful medical justification.

What Exactly Does “Specialist-Only Prescribing” Mean?

Only doctors on the General Medical Council’s specialist registers, such as neurologists or pain specialists, can prescribe cannabis-based medicines. General Practitioners (GPs) cannot initiate such prescriptions, limiting broader NHS access.

The reason is simple: cannabis medicines are considered complex and potentially risky. There is limited long-term research, and the medical community wants oversight from those trained to understand nuances of dosage, side effects, and interaction with other drugs.

Takeaway: Since 2018, cannabis medicines can be prescribed by specialists only, reflecting cautious medical use rather than widespread approval.

Why Cannabis Remains Illegal Under the 1971 Misuse of Drugs Act

Despite progress, cannabis remains a Class B controlled drug under the Misuse of Drugs Act 1971. This means:

• Recreational use, possession, supply, and cultivation outside licensed parameters are illegal and subject to criminal prosecution.
• The legal framework views cannabis as having a high potential for abuse with no medically legitimate use outside specialist prescribing.

The Act predates much modern research, so until robust clinical evidence and reform legislation occur, cannabis in its raw or unregulated forms stays illegal. The 2018 prescription route is an exception, not a full legalisation or normalisation.

MHRA Regulation: Safety, Quality, and Efficacy of Licensed Cannabis Medicines

The MHRA’s role is to safeguard public health by ensuring medicines meet standards of safety, quality, and efficacy. Only cannabis-based medicines with thorough clinical trials and regulatory approval can be licensed for prescription.

At present, there are only a handful of licensed medicines only approved for prescription, notably:

• Sativex (nabiximols) — a mouth spray containing THC and CBD, licensed for spasticity in multiple sclerosis.
• Epidyolex (cannabidiol or CBD) — licensed for certain rare epilepsy syndromes such as Dravet syndrome.

These products have passed MHRA scrutiny regarding their manufacturing standards, clinical trial evidence, and consistent dosing—key hallmarks that unlicensed cannabis products on the market often lack.

Licensed vs Unlicensed Cannabis Products

Feature Licensed Medicines (e.g., Sativex, Epidyolex) Unlicensed Cannabis Products MHRA Approval Yes, fully approved No formal approval Safety and Quality Controls Strict manufacturing and QA Variable, often unclear Clinical Evidence Robust trial data Limited or anecdotal Availability Prescribed by specialists on NHS or private basis Mostly private, often grey market or imported Cost and NHS Funding Usually NHS funded for licensed indications Usually paid out of pocket

Takeaway: Only licensed cannabis medicines meet the regulator's standards; unlicensed products lack this assurance and remain subject to unlicensed prescribing rules.

Unlicensed Prescribing Basis: How Do Patients Access Cannabis Medicines Outside Licences?

Where a patient’s condition does not fit a licensed medicine’s approved use, specialist doctors may prescribe cannabis medicines unlicensed but based on clinical judgment and patient need. This is called prescribing “unlicensed medicines on a named-patient basis.”

Though legal and accepted in UK medical practice, unlicensed prescribing carries extra responsibility:

• The prescriber must be confident the medicine is in the patient’s best interest.
• There’s limited standardisation or regulatory oversight of unlicensed cannabis products, raising concerns over consistency and safety.
• Such prescriptions often must be privately sourced, for example via companies like Nationwide Pharmacies, who specialise in supplying difficult-to-source medications including unlicensed cannabis products.

Despite the option to prescribe unlicensed cannabis medicines, NHS funding for these is rare. Consequently, most patients fund their treatment privately, adding cost and access challenges.

Takeaway: Unlicensed prescribing offers a route for access but comes with caveats on safety, regulation, and cost, reinforcing why licensed products remain central to approved medical use.

Role of Companies Like Nationwide Pharmacies

Nationwide Pharmacies is one of the UK’s prominent specialist providers of difficult-to-obtain medicines, including unlicensed cannabis products. They operate within the legal framework, sourcing from quality-assured suppliers and ensuring compliance with regulations.

Their role is crucial because many patients prescribed unlicensed cannabis medicines by specialists cannot access these through standard NHS pharmacies, which usually stock only licensed medicines.

By offering a thorough supply chain and patient support, Nationwide Pharmacies bridges the gap between specialist prescribing and patient access, but it’s essential to remember these products are not MHRA approved medicines in most cases.

Takeaway: Specialist pharmacies like Nationwide Pharmacies facilitate access to unlicensed cannabis medicines but do not alter regulatory or legal status.

Summary: What Does This Mean For Patients and Public Understanding?

1. The UK medicines regulator, MHRA, does not approve most cannabis products; only a handful of licensed cannabis-based medicines have passed its stringent requirements.
2. Cannabis remains a Class B drug under the 1971 Misuse of Drugs Act, meaning its recreational use is illegal; medical prescriptions are a tightly regulated exception.
3. The 2018 policy allowed specialist doctors to legally prescribe cannabis medicines to patients where clinically appropriate, but this is not a widespread NHS or public legalisation.
4. Access is restricted to specialist-only prescribing, with GPs not able to initiate, limiting NHS availability.
5. Most cannabis products outside licensed medicines are unlicensed, prescribed on a named-patient basis—often sourced privately with suppliers like Nationwide Pharmacies.

Understanding this nuanced regulatory and legal landscape helps prevent misleading claims such as “weed is now legal” or “cannabis products are freely available on the NHS,” neither of which are accurate.

In brief: Only licensed cannabis medicines like Sativex and Epidyolex are approved by the UK regulator; most cannabis products remain unapproved, unlicensed, and tightly controlled.